Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Alimera Sciences stock price, quote, forecast and news

ALIM
US0162592028
A2PVHE

Price

5.59
Today +/-
+0.01
Today %
+0.18 %
P

Alimera Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Alimera Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Alimera Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Alimera Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Alimera Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Alimera Sciences Stock Price History

DateAlimera Sciences Price
8/23/20245.59 undefined
8/22/20245.58 undefined
8/21/20245.59 undefined
8/20/20245.58 undefined
8/19/20245.59 undefined
8/16/20245.58 undefined
8/15/20245.58 undefined
8/14/20245.59 undefined
8/13/20245.60 undefined
8/12/20245.60 undefined
8/9/20245.59 undefined
8/8/20245.57 undefined
8/7/20245.55 undefined
8/6/20245.55 undefined
8/5/20245.55 undefined
8/2/20245.56 undefined
8/1/20245.56 undefined
7/31/20245.56 undefined
7/30/20245.55 undefined
7/29/20245.56 undefined

Alimera Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Alimera Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Alimera Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Alimera Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Alimera Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Alimera Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Alimera Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Alimera Sciences’s growth potential.

Alimera Sciences Revenue, EBIT and net profit per share

DateAlimera Sciences RevenueAlimera Sciences EBITAlimera Sciences Net Income
2029e278.83 M undefined0 undefined108.48 M undefined
2028e234.04 M undefined102.83 M undefined83.36 M undefined
2027e195.32 M undefined72.89 M undefined53.97 M undefined
2026e138.63 M undefined33.41 M undefined22.98 M undefined
2025e123.51 M undefined19.71 M undefined10.15 M undefined
2024e108.13 M undefined5.06 M undefined-6.77 M undefined
202380.75 M undefined-1.93 M undefined-21.39 M undefined
202254.13 M undefined-11.64 M undefined-18.11 M undefined
202159.03 M undefined-200,000 undefined-4.37 M undefined
202050.82 M undefined-500,000 undefined-5.34 M undefined
201953.94 M undefined-5.27 M undefined-10.44 M undefined
201846.6 M undefined-9.67 M undefined21.95 M undefined
201735.91 M undefined-16.45 M undefined-22 M undefined
201634.33 M undefined-27.85 M undefined-33.17 M undefined
201522.44 M undefined-39 M undefined-30.65 M undefined
20148.42 M undefined-32.95 M undefined-36.66 M undefined
20131.87 M undefined-34.41 M undefined-51.18 M undefined
20120 undefined-22.04 M undefined-19.75 M undefined
20110 undefined-21.41 M undefined-22.52 M undefined
20100 undefined-22.07 M undefined-16.96 M undefined
20090 undefined-19.22 M undefined-52.42 M undefined
20080 undefined-50.08 M undefined-68.76 M undefined
20070 undefined-12.52 M undefined-10.64 M undefined
20060 undefined-10.38 M undefined-16.76 M undefined
20050 undefined-6.08 M undefined-15.35 M undefined
20040 undefined-3.82 M undefined-7.11 M undefined

Alimera Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000000018223435465350595480108123138195234278
-----------700.00175.0054.552.9431.4315.22-5.6618.00-8.4748.1535.0013.8912.2041.3020.0018.80
-----------75.0090.9191.1891.4391.3088.6886.0088.1485.1986.25------
000000000006203132424743524669000000
0-3-6-10-12-50-19-22-21-22-34-32-39-27-16-9-500-11-151933721020
-----------3,400.00-400.00-177.27-79.41-45.71-19.57-9.43---20.37-1.254.6315.4523.9136.9243.59-
0-7-15-16-10-68-52-16-22-19-51-36-30-33-2221-10-5-4-18-21-610225383108
--114.296.67-37.50580.00-23.53-69.2337.50-13.64168.42-29.41-16.6710.00-33.33-195.45-147.62-50.00-20.00350.0016.67-71.43-266.67120.00140.9156.6030.12
4.894.894.894.891.51.511.5222.1731.3631.4631.5840.444.4552.866.995.924.775.126.6725.56000000
---------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Alimera Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Alimera Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200620072008200920102011201220132014201520162017201820192020202120222023
27.220.817.94.954.833.649.612.676.731.13124.1139.411.216.55.312.06
0.50.1000000.50.99.813.811.417.319.317.219.119.634.55
0.71.90000000000000000
0.7000000.71.81.71.60.41.52.41.42.72.71.61.88
1.71.31.61.41.40.92.13.83.22.72.12.32.12.63.73.82.93.94
30.824.119.56.356.234.552.418.782.545.247.339.334.832.734.842.129.452.42
0.40.40.80.30.20.20.111.72.61.81.41.422.44.53.93.59
00000000000000080020052
000000000000000000
0000000024.522.520.618.716.714.812.810.9997.36
000000000000000000
0000000000.20.40.51.20.70.80.10.10.1
0.40.40.80.30.20.20.1126.225.322.820.619.317.51616.313.2101.1
31.224.520.36.656.434.752.519.7108.770.570.159.954.150.250.858.442.6153.52
63.168.1103.1113.50.30.332.332.369.269.369.469.53130.419.319.319.30.52
2.62.93.56.3233.3235.6237.5240.1292.9299.4330.8341.6346.1350.1365.8377.2378.2462.45
-40-50.7-119.4-171.8-188.4-211-230.7-276.9-311.8-341.2-373.4-395.4-373.4-383.9-392.5-397.3-415.4-414.09
0000000-0.5-0.8-1.1-1.3-0.8-1-1.1-0.6-1.8-3-2.71
000000000000000000
25.720.3-12.8-5245.224.939.1-549.526.425.514.92.7-4.5-8-2.6-20.946.17
1.70.81.61.81.71.921.75455.96.47.17.58.710.18.25
22.82.33.32.71.61.20.933.63.83.63.64.73.23.6413.47
1.90.611.20.80.72.60.61.50.30.20000000
000000000000000000
0004.51.22.52.31.71320.20.20.20.31.70.325.60.19
5.64.24.910.86.46.78.14.910.539.99.29.710.212.112.412.639.721.91
001510.54.82.90.73.232.30.633.434.638.238.842.943.118.764.49
000000000000000000
0013.237.400.14.616.416.33.62.20.8343.65.5520.95
0028.247.94.835.319.648.64.235.635.441.242.846.548.623.785.44
5.64.233.158.711.29.713.424.559.144.144.845.151.454.958.961.263.4107.35
31.324.520.36.756.434.652.519.5108.670.570.36054.150.450.958.642.5153.52
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Alimera Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Alimera Sciences's financial health and stability.

Assets

Alimera Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Alimera Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Alimera Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Alimera Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
-13-12-5-61-44-13-22-19-46-35-30-33-22-16-10-5-4-18-20
0000100000222222228
0000000000000000000
00001000-65-1000-40-1-12-15
0-7-72924-740168-1101111530314
0000100001434344446
0000000000000000000
-12-20-12-32-17-22-20-21-37-24-45-25-12-11-4-2-3-9-14
000000000000000000-75
09600-222500-2500000000-75
09600-222500-25000000000
0000000000000000000
00000-80-21290004230022
3215029479040085126500010079
3215029468037111402550039096
------2.00----1.00--1.00--3.00-2.00----5.00
0000000000000000000
194-6-2-1323416-3664-450-6-11-315-116
-13.09-21.22-13.11-32.76-17.61-22.18-20.83-21.2-38.79-25.14-45.81-25.29-13.11-11.73-4.32-2.81-3.84-10.24-89.79
0000000000000000000

Alimera Sciences stock margins

The Alimera Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Alimera Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Alimera Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Alimera Sciences's sales revenue. A higher gross margin percentage indicates that the Alimera Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Alimera Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Alimera Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Alimera Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Alimera Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Alimera Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Alimera Sciences Margin History

Alimera Sciences Gross marginAlimera Sciences Profit marginAlimera Sciences EBIT marginAlimera Sciences Profit margin
2029e86.58 %0 %38.9 %
2028e86.58 %43.94 %35.62 %
2027e86.58 %37.32 %27.63 %
2026e86.58 %24.1 %16.58 %
2025e86.58 %15.95 %8.22 %
2024e86.58 %4.68 %-6.26 %
202386.58 %-2.39 %-26.49 %
202285.26 %-21.5 %-33.46 %
202188.09 %-0.34 %-7.4 %
202086.34 %-0.98 %-10.51 %
201987.73 %-9.77 %-19.35 %
201890.75 %-20.75 %47.1 %
201790.42 %-45.81 %-61.26 %
201693.18 %-81.12 %-96.62 %
201592.16 %-173.8 %-136.59 %
201482.9 %-391.33 %-435.39 %
20130.53 %-1,840.11 %-2,736.9 %
201286.58 %0 %0 %
201186.58 %0 %0 %
201086.58 %0 %0 %
200986.58 %0 %0 %
200886.58 %0 %0 %
200786.58 %0 %0 %
200686.58 %0 %0 %
200586.58 %0 %0 %
200486.58 %0 %0 %

Alimera Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Alimera Sciences earnings per share therefore indicates how much revenue Alimera Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alimera Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alimera Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alimera Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alimera Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Alimera Sciences Revenue, EBIT and net profit per share

DateAlimera Sciences Sales per ShareAlimera Sciences EBIT per shareAlimera Sciences Earnings per Share
2029e5.32 undefined0 undefined2.07 undefined
2028e4.47 undefined0 undefined1.59 undefined
2027e3.73 undefined0 undefined1.03 undefined
2026e2.65 undefined0 undefined0.44 undefined
2025e2.36 undefined0 undefined0.19 undefined
2024e2.06 undefined0 undefined-0.13 undefined
20233.16 undefined-0.08 undefined-0.84 undefined
20227.73 undefined-1.66 undefined-2.59 undefined
20218.94 undefined-0.03 undefined-0.66 undefined
20209.93 undefined-0.1 undefined-1.04 undefined
201911.31 undefined-1.1 undefined-2.19 undefined
20187.87 undefined-1.63 undefined3.71 undefined
20170.54 undefined-0.25 undefined-0.33 undefined
20160.65 undefined-0.53 undefined-0.63 undefined
20150.5 undefined-0.88 undefined-0.69 undefined
20140.21 undefined-0.82 undefined-0.91 undefined
20130.06 undefined-1.09 undefined-1.62 undefined
20120 undefined-0.7 undefined-0.63 undefined
20110 undefined-0.68 undefined-0.72 undefined
20100 undefined-1 undefined-0.76 undefined
20090 undefined-12.64 undefined-34.49 undefined
20080 undefined-33.17 undefined-45.54 undefined
20070 undefined-8.35 undefined-7.09 undefined
20060 undefined-2.12 undefined-3.43 undefined
20050 undefined-1.24 undefined-3.14 undefined
20040 undefined-0.78 undefined-1.45 undefined

Alimera Sciences business model

Alimera Sciences Inc. is a leading global company specializing in the development of pharmaceutical products for eye diseases. The company was founded in 2003 in Atlanta, Georgia, USA and has since made remarkable progress in developing innovative clinical solutions. Business model: Alimera Sciences Inc. strives to utilize the latest technologies and methods in ophthalmology to improve the quality of life for patients with eye diseases. The company works closely with leading research institutions to incorporate the latest scientific findings into its product development. Alimera Sciences has a wide range of research areas to develop innovative solutions for conditions such as diabetes-related macular degeneration, retinopathy, uveitis, and other eye diseases. The company also places great value on collaboration with the medical community and actively advocates for the improvement of patient care and the education of eye experts. Products: Alimera Sciences' products are specialized in the treatment of eye diseases and utilize various technologies to improve patients' quality of life. The flagship product of Alimera Sciences is Iluvien, an intravitreal implant for the treatment of chronic diabetic macular edema (DME). Iluvien is the only commercially available DME implant and offers a unique treatment option for patients who do not respond to standard treatments. In addition to Iluvien, Alimera Sciences also manufactures a range of other products, including Ozurdex, a steroid-containing intravitreal implant for the treatment of retinopathy and uveitis. Alimera Sciences also has an extensive portfolio of investigational drugs, many of which are in various stages of clinical development. History: Alimera Sciences was founded in 2003 by Daniel C. Myers and David R. Holland in Atlanta, Georgia. The company originally specialized in developing drugs for the treatment of lung diseases, but over the years, its focus shifted to ophthalmology. In 2011, the company received FDA approval for Iluvien, which was a significant milestone in the history of Alimera Sciences. Since then, the company has continuously expanded its presence in ophthalmology by increasing its research and development efforts and forming partnerships with key medical organizations and institutions. Today, Alimera Sciences is a leading provider of pharmaceutical solutions for eye diseases, focusing on the development of drugs to improve patients' quality of life and enhance medical care. Conclusion: Overall, Alimera Sciences is an innovative company specializing in the development of drugs for the treatment of eye diseases. In its 18 years of existence, the company has achieved an impressive success story and continues its efforts to attain a leading position in the ophthalmic industry. With insights and experience in medical history and the knowledge of important medical professionals, the company is prepared to continuously meet the medical needs and expectations of patients with eye diseases. Alimera Sciences is one of the most popular companies on Eulerpool.com.

Alimera Sciences SWOT Analysis

Strengths

Alimera Sciences Inc is a leading biopharmaceutical company in the field of ophthalmology, focusing on retina diseases.

The company has innovative and advanced products targeting chronic and acute retinal conditions.

Alimera Sciences has a strong R&D team, constantly researching and developing new treatments.

Weaknesses

The company heavily relies on a limited number of products, which may expose it to market volatility and potential revenue fluctuations.

Alimera Sciences has a comparatively small market share and faces strong competition from larger pharmaceutical companies in the ophthalmology sector.

Due to the nature of its products, Alimera Sciences may encounter regulatory hurdles and strict approval processes, leading to delays in product launches.

Opportunities

The increasing prevalence of retinal diseases and the aging population present significant growth opportunities for Alimera Sciences.

Expanding into international markets can help the company diversify its revenue streams and reduce dependence on the domestic market.

Collaborations with academic institutions and healthcare organizations can facilitate clinical trials and enhance the company's research capabilities.

Threats

Intense competition from both established and emerging players in the ophthalmology market poses a threat to Alimera Sciences' market share.

Changing regulatory requirements and healthcare policies may restrict access to certain markets or increase pricing pressures.

Any adverse effects or safety concerns related to Alimera Sciences' products could lead to litigation or damage the company's reputation.

Alimera Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Alimera Sciences historical P/E ratio, EBIT, and P/S ratio.

Alimera Sciences shares outstanding

The number of shares was Alimera Sciences in 2023 — This indicates how many shares 25.562 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alimera Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alimera Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alimera Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alimera Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Alimera Sciences Stock splits

In Alimera Sciences's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Alimera Sciences.

Alimera Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.04 -0.06  (-60.43 %)2024 Q2
3/31/2024-0.06 -0.12  (-107.61 %)2024 Q1
12/31/20230 -0.07  (0 %)2023 Q4
9/30/2023-0.07 -0.06  (8.81 %)2023 Q3
6/30/20230.02 -1.32  (-8,727.45 %)2023 Q2
3/31/2023-0.33 -0.71  (-117.52 %)2023 Q1
12/31/2022-0.34 -0.54  (-58.03 %)2022 Q4
9/30/2022-0.41 -0.75  (-82.3 %)2022 Q3
6/30/2022-0.56 -0.45  (20.27 %)2022 Q2
3/31/2022-0.7 -0.85  (-20.77 %)2022 Q1
1
2
3
4
5
...
6

Alimera Sciences list of shareholders

%
Name
Stocks
Change
Date
7.63 % Stonepine Capital Management, LLC3,999,45915,77312/31/2023
6.11 % Boothbay Fund Management, LLC3,198,708012/31/2023
5.08 % Altium Capital Management LP2,660,000-274,10812/31/2023
4.17 % Lytton (Laurence W)2,185,364-799,43912/31/2023
4.14 % Clearline Capital LP2,169,143-166,15012/31/2023
32.13 % Caligan Partners, LP16,835,154012/31/2023
3.19 % AIGH Capital Management, LLC.1,669,426-109,43712/31/2023
25.98 % Velan Capital Investment Management LP13,608,533012/31/2023
2.19 % Ocumension Therapeutics1,144,94506/8/2023
1.74 % Morgan Stanley & Co. LLC910,832250,00012/31/2023
1
2
3
4
5
...
7

Alimera Sciences Executives and Management Board

Mr. Richard Eiswirth55
Alimera Sciences President, Chief Executive Officer, Director (since 2005)
Compensation 964,198
Dr. Philip Ashman58
Alimera Sciences President - International Operations
Compensation 609,656
Mr. David Holland59
Alimera Sciences Chief Marketing Officer, Senior Vice President - Corporate Communications and Managed Markets
Compensation 541,715
Mr. C. Daniel Myers69
Alimera Sciences Non-Executive Chairman of the Board (since 2003)
Compensation 85,000
Mr. Peter Pizzo56
Alimera Sciences Independent Director
Compensation 64,000
1
2
3

Most common questions regarding Alimera Sciences

What values and corporate philosophy does Alimera Sciences represent?

Alimera Sciences Inc represents a commitment to improving the lives of patients with retinal diseases. The company is dedicated to developing and commercializing innovative prescription products that address the unmet medical needs in ophthalmology. Alimera Sciences focuses on the development of sustained-release treatments, such as ILUVIEN®, which is designed to provide long-term reduction of vision loss associated with diabetic macular edema. With a patient-centric approach, Alimera Sciences strives to enhance visual outcomes and quality of life for individuals worldwide. The company's corporate philosophy emphasizes scientific excellence, ethical behavior, and a dedication to advancing eye care through research and development.

In which countries and regions is Alimera Sciences primarily present?

Alimera Sciences Inc is primarily present in the United States, Europe, and the Middle East.

What significant milestones has the company Alimera Sciences achieved?

Alimera Sciences Inc has achieved significant milestones since its inception. Notably, the company has successfully developed and commercialized ILUVIEN, a sustained-release intravitreal implant for the treatment of diabetic macular edema (DME). This innovative product has been approved by regulatory authorities in various countries, including Europe and the United States. Additionally, Alimera Sciences Inc has expanded its market reach through strategic partnerships and collaborations with influential pharmaceutical companies. The company's commitment to ongoing research and development has led to advancements in ocular drug delivery systems, positioning Alimera Sciences Inc as a leading player in the ophthalmic pharmaceutical industry.

What is the history and background of the company Alimera Sciences?

Alimera Sciences Inc. is a pharmaceutical company established in 2003 and headquartered in Atlanta, Georgia. It specializes in developing and commercializing prescription ophthalmology products for the treatment of retinal diseases. Alimera Sciences Inc. is primarily known for its flagship product, ILUVIEN®, which is an injectable steroid implant used for the treatment of diabetic macular edema (DME) in patients who have been previously treated but have not responded adequately to other therapies. With its innovative products and focus on retinal diseases, Alimera Sciences Inc. continues to make significant contributions to the healthcare industry.

Who are the main competitors of Alimera Sciences in the market?

The main competitors of Alimera Sciences Inc in the market are pharmaceutical companies that specialize in ophthalmology and the treatment of various eye diseases. Some of the prominent competitors include BioSpecifics Technologies Corp, Eyenovia Inc, Ocular Therapeutix Inc, and Novartis AG. These companies also offer innovative solutions, products, and therapies for eye conditions, competing with Alimera Sciences Inc in the ophthalmic pharmaceutical market.

In which industries is Alimera Sciences primarily active?

Alimera Sciences Inc is primarily active in the pharmaceutical industry.

What is the business model of Alimera Sciences?

The business model of Alimera Sciences Inc is focused on the research, development, and commercialization of ophthalmic pharmaceuticals. The company specializes in offering innovative treatments for retinal diseases, primarily diabetic macular edema (DME), a leading cause of vision loss. Alimera Sciences Inc primarily operates through its flagship product, ILUVIEN, which is a sustained-release intravitreal implant designed to deliver a continuous, low-dose of medication to the retina over an extended period. By providing long-lasting therapies, Alimera Sciences Inc aims to improve patient outcomes and reduce treatment burdens. With a devoted focus on retinal diseases, the company continues to expand its portfolio and enhance the quality of life for individuals with vision impairments.

What is the P/E ratio of Alimera Sciences 2024?

The Alimera Sciences P/E ratio is -21.11.

What is the P/S ratio of Alimera Sciences 2024?

The Alimera Sciences P/S ratio is 1.32.

What is the AlleAktien quality score of Alimera Sciences?

The AlleAktien quality score for Alimera Sciences is 5/10.

What is the revenue of Alimera Sciences 2024?

The expected Alimera Sciences revenue is 108.13 M USD.

How high is the profit of Alimera Sciences 2024?

The expected Alimera Sciences profit is -6.77 M USD.

What is the business model of Alimera Sciences

Alimera Sciences Inc is a biopharmaceutical company based in Georgia that specializes in the development and commercialization of therapies for eye diseases. The company was founded in 2003 and has since built various collaborations and partnerships with other companies. Alimera Sciences specializes in the development of medications for eye diseases, particularly Diabetic Macular Edema (DME) and Uveitis. The company's flagship product is ILUVIEN®, an intravitreal implant that continuously releases the glucocorticoid fluocinolone acetonide to slow the progression of vision loss. ILUVIEN® was approved in the United States in 2012 and has been on the market in Europe since 2013. Alimera Sciences Inc. serves a rapidly growing market as diabetic retinopathy and age-related macular degeneration (AMD) increasingly lead to significant impairments in vision. However, treating diabetic retinopathy and AMD is very challenging, and there are concerns about the safety and effectiveness of existing therapies. Alimera Sciences' business model is based on developing and bringing to market innovative medications and therapies that address the gaps in existing treatment options. The company works closely with other companies and research institutions to develop new technologies and treatment approaches. Alimera Sciences has established several marketing partnerships in various countries to distribute its products worldwide. The company has entered into strategic partnerships with major pharmaceutical companies such as Bausch + Lomb, Brill Pharma, and Mundipharma to enable broader marketing of ILUVIEN®. The company has also focused on researching and developing new technologies and therapies to harness the potential in other eye diseases, such as Uveitis. The company recently launched a novel antiviral therapy for Uveitis, which is still in the clinical trial stage. Alimera Sciences also maintains a pipeline of drugs in various stages of development to expand its portfolio of eye therapies. Alimera Sciences has experienced significant growth in recent years. The company achieved a net revenue of $51 million in 2019 and expects further growth in the coming years through the introduction of new products and expansion of its geographical reach. Overall, Alimera Sciences is a biopharmaceutical company specializing in the development and commercialization of therapies for eye diseases. The company has developed an innovative portfolio of products and technologies tailored to the needs of the rapidly growing market. Alimera Sciences has established strategic partnerships to facilitate the global marketing of its products. The company maintains a strong pipeline of drugs in various stages of development aimed at further closing the gaps in existing treatment options.

What is the Alimera Sciences dividend?

Alimera Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does Alimera Sciences pay dividends?

The dividend cannot currently be calculated for Alimera Sciences or the company does not pay out a dividend.

What is the Alimera Sciences ISIN?

The ISIN of Alimera Sciences is US0162592028.

What is the Alimera Sciences WKN?

The WKN of Alimera Sciences is A2PVHE.

What is the Alimera Sciences ticker?

The ticker of Alimera Sciences is ALIM.

How much dividend does Alimera Sciences pay?

Over the past 12 months, Alimera Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alimera Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Alimera Sciences?

The current dividend yield of Alimera Sciences is .

When does Alimera Sciences pay dividends?

Alimera Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alimera Sciences?

Alimera Sciences paid dividends every year for the past 0 years.

What is the dividend of Alimera Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alimera Sciences located?

Alimera Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alimera Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alimera Sciences from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Alimera Sciences pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Alimera Sciences in the year 2023?

In the year 2023, Alimera Sciences distributed 0 USD as dividends.

In which currency does Alimera Sciences pay out the dividend?

The dividends of Alimera Sciences are distributed in USD.

All fundamentals about Alimera Sciences

Our stock analysis for Alimera Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alimera Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.